Summary
GE HealthCare Technologies Inc. (GEHC) reported a solid third quarter for 2024, with total revenues reaching $4.86 billion, a 1% increase both on a reported and organic basis compared to the prior year. This growth was driven by a 2% increase in service revenues and a slight uptick in product sales, despite challenges in the China market due to an ongoing anti-corruption campaign and delayed stimulus program. Operating income saw a significant increase of 10% to $676 million, and net income attributable to GE HealthCare common stockholders rose by 25% to $470 million, reflecting strong cost productivity and favorable pricing. The company also demonstrated robust cash flow generation, with operating cash flow of $1.04 billion for the nine-month period. Financially, GEHC maintained a strong balance sheet with $3.57 billion in cash, cash equivalents, and restricted cash as of September 30, 2024. The company successfully issued $1 billion in senior unsecured notes, strengthening its liquidity position. Remaining Performance Obligations (RPO) stood at $14.56 billion, indicating a healthy future revenue pipeline, though slightly down 1% from the end of 2023. The company's strategic acquisitions, such as MIM Software, are being integrated, and management remains optimistic about long-term growth prospects, particularly in expanding healthcare access globally.
Financial Highlights
48 data points| Revenue | $4.86B |
| Gross Profit | $2.03B |
| R&D Expenses | $316.00M |
| SG&A Expenses | $1.03B |
| Operating Expenses | $1.35B |
| Operating Income | $676.00M |
| Net Income | $470.00M |
| EPS (Basic) | $1.03 |
| EPS (Diluted) | $1.02 |
| Shares Outstanding (Basic) | 457.00M |
| Shares Outstanding (Diluted) | 459.00M |
Key Highlights
- 1Total revenues grew 1% to $4.86 billion for Q3 2024, with organic revenue also increasing by 1%.
- 2Operating income increased by 10% to $676 million, with operating margin improving by 110 basis points to 13.9%.
- 3Net income attributable to GE HealthCare common stockholders increased by 25% to $470 million, reflecting strong operational execution and cost management.
- 4The company successfully issued $1 billion in senior unsecured notes, bolstering its liquidity and managing its debt profile.
- 5Remaining Performance Obligations (RPO) stood at $14.56 billion as of September 30, 2024, providing visibility into future revenue.
- 6Acquisition of MIM Software for approximately $259 million was completed, adding AI solutions to the Imaging segment.
- 7Despite challenges in China, the Pharmaceutical Diagnostics (PDx) segment showed strong growth of 6% in Q3 2024, driven by volume, price increases, and new product introductions.